Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
about
Ex vivo cytosolic delivery of functional macromolecules to immune cellsImproved endpoints for cancer immunotherapy trialsOverall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancerA phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neuImmunobiology and immunotherapy in genitourinary malignanciesA Perspective of Immunotherapy for Prostate CancerPerspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigmTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerThe Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsImproving the clinical impact of biomaterials in cancer immunotherapy.Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression ModelApplication of radiation technology in vaccines developmentMetastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyTherapeutic cancer vaccines: past, present, and futureFrom bench to bedside: immunotherapy for prostate cancerFrom tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumorsEndpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsRecent progress in pharmaceutical therapies for castration-resistant prostate cancerProstate cancer: ESMO Consensus Conference Guidelines 2012Prostate cancer treatment: the times they are a' changin'What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidenceA Urologist's Personal View of Prostate CancerLung cancer vaccines: current status and future prospectsDifferent maturation cocktails provide dendritic cells with different chemoattractive properties.The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Structural and functional analysis of human prostatic acid phosphatase.A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)Theranostic mRNA-loaded microbubbles in the lymphatics of dogs: implications for drug delivery.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.New developments in the medical management of prostate cancer.Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.Immunotherapy in genitourinary malignancies.Geriatric considerations in the treatment of advanced prostate cancerAngiogenesis inhibitors in the treatment of prostate cancer.Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implicationsNovel targeted therapeutics for metastatic castration-resistant prostate cancer.At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.Vaccines against human carcinomas: strategies to improve antitumor immune responses.Is cancer vaccination feasible at older age?
P2860
Q21131808-F0D6C727-95EF-4A82-AFB6-AE5E8AA0A6FAQ24603112-E0FAC279-F96A-4C26-A6C3-322AFF7F772BQ24632187-0E0A4740-054F-43C4-AF4D-4A6377A57B64Q24649530-F2E74726-A103-4B77-8E1D-3C8E1678BF88Q26738668-34E25777-2C13-4062-BB33-89E4E2C4D788Q26741277-9469D030-6A11-46F8-BC75-8903D505D536Q26747699-3042C340-2D36-4F53-8C80-3699682EEF1AQ26750620-DCD7083B-EA8C-4149-A6BE-3B2637D8318CQ26750672-1AEB8CF5-680E-41F3-A38C-1DE0396FC2B2Q26766267-2206E060-5E78-4BCA-99EF-CCF48C9D0A42Q26783861-1C715A86-824B-4416-9979-45870020E477Q26798165-B4F1FA44-0CC2-4AF9-AD38-B530BFA8114DQ26825053-A5FA8554-3EB3-4654-ADFC-91C9D3BC1AA4Q26863283-B3125B8B-A05B-4DEB-8937-0DD4E35D874CQ26864390-45A4EFA9-FF68-49A9-BBA8-BB1714719913Q26865532-F1789D9C-769A-4004-947A-B0DA8B4EAD1EQ27008070-8A6AF870-554C-426D-80CB-590AE687D614Q27014829-3F7CBE8F-F0ED-4884-8E54-F3CE3B9745F5Q27022567-B87BDC1E-9A6C-4F35-9D6B-FCEA4190C503Q27022847-3DF29414-05BD-4ADA-B9B4-9DC7876365CDQ27025607-D809785E-EC3D-4080-BEF3-70B6E9DD9693Q28066240-F19709C3-E5A2-469C-A77D-0DEC768173B3Q28072919-FC0541AE-CE8B-4A2D-915C-8F77D021134AQ28080849-4D83F79E-00A5-4666-8032-99695F86A3AEQ30315866-395F2F10-5898-4C72-B72E-C2DFD124051CQ30317628-241BFA74-FBBD-45CC-A470-8D94E2393175Q30391641-20050873-F29D-4338-BBAD-272B0B4301F5Q30411499-A4102964-8B50-441F-B86F-7E7AE04E50EBQ30422136-A0BD34E7-644D-45EB-821D-18D861922977Q30846001-7C815794-BC97-41F7-9650-17A1F8292269Q33566738-E4568991-51B6-49A9-8A03-BBBC57DC0F5DQ33586724-13910295-417B-4855-B305-F5FF735A8758Q33593800-E3AD399F-B995-4574-BF3D-FFE0217E73BAQ33598327-D65D6CB6-8E33-4495-A49A-1A629C6EAC40Q33611121-2B16D839-E06B-4B2C-B8EC-C08DB8248CA0Q33621393-5713F946-6EFB-4EA5-911B-C2D5BFF45544Q33642278-060E98C5-E0C0-400F-8B34-39F51F310633Q33732329-8ADDAA12-E190-4D9C-B873-3436E9551A7BQ33734281-9BE402A8-69FF-4C8F-AC42-3D67FD56CA6DQ33739907-571B9CD0-FDC4-4BC3-A9FD-B8F355150C64
P2860
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Placebo-controlled phase III t ...... ne refractory prostate cancer.
@ast
Placebo-controlled phase III t ...... ne refractory prostate cancer.
@en
Placebo-controlled phase III t ...... ne refractory prostate cancer.
@nl
type
label
Placebo-controlled phase III t ...... ne refractory prostate cancer.
@ast
Placebo-controlled phase III t ...... ne refractory prostate cancer.
@en
Placebo-controlled phase III t ...... ne refractory prostate cancer.
@nl
prefLabel
Placebo-controlled phase III t ...... ne refractory prostate cancer.
@ast
Placebo-controlled phase III t ...... ne refractory prostate cancer.
@en
Placebo-controlled phase III t ...... ne refractory prostate cancer.
@nl
P2093
P921
P356
P1476
Placebo-controlled phase III t ...... ne refractory prostate cancer.
@en
P2093
Celestia S Higano
Charles H Redfern
Eric J Small
Frank H Valone
John J Nemunaitis
Lori A Jones
Paul F Schellhammer
Robert M Hershberg
Suleman S Verjee
P304
P356
10.1200/JCO.2005.04.5252
P407
P577
2006-07-01T00:00:00Z